SIRONA BIOCHEM WKN: A0RM6R ISIN: CA82967M1005 Kürzel: ZSB Forum: Aktien Thema: Hauptdiskussion

Das denke ich auch. Lasse mich leider zu sehr emotional vom Aktienkurs leiten. Versuche mich mal wieder mehr auf die Fakten zu konzentrieren und da sehe ich bis auf die Kommunikation nichts was wirklich falsch läuft

Hatte ja Micha schon einmal geposted den Artikel. Echt interessant und zeigt auf, warum sich AbbieVie für unser TFC-1067 final entschieden hat. Da wird wohl noch einiges kommen!!!

C&T: What are some next directions for the body and skin care market? PM: There are many emerging trends. One that I would go back to, and that I think is still an unmet need (as patients and consumers are still not happy) is the area of pigmentation and addressing concerns of uneven skin tone. This is because it is such a complex biology, etiology that is different for different skin types, races, ethnicities—and there are different kinds of pigmentation; from PIH to melasma to uneven tone to solar lentigines. There are Rx treatments available with hydroquinone that are very effective; however, not a lot of patients can tolerate them. So I think we have an opportunity to develop some strategies through a multimodal approach to the melanin lifecycle to address signs of pigmentation, taking this diverse population into account.A final paper I will mention from the Journal of Cosmetic Dermatology describes combining a circadian-based antioxidant system with a brightening product that uses a multimodal melanin lifecycle approach. This was interesting because it was tested in Asian consumers and the authors were able to further dissect the segments of Asian consumers. This is because the needs are different for someone from East Asia versus Southeast Asia versus the Indian sub-continent. So I think there is an opportunity to further understand sub-population bases. Pigmentation is not something new but I do see the science is emerging in not only how we target and address it, but also in how we test these products with our consumers.

C&T: In terms of formulating skin and body care, what trends do you see moving forward? PM: Consumers are actually becoming a lot more sophisticated—they want to learn about ingredients, about the science, about how we create formulations—so we certainly have an opportunity to educate and be more transparent. With that, I think it is time to go back to the basics in formulation design, i.e., how it used to be done. This means, as I mentioned, understanding that interactions of ingredients and the effects of certain critical formulation parameters such as pH ranges are important for not only skin interaction, but also the efficacy of the ingredient. In addition, as I previously stated, we need to understand the actual constituents of naturals better and how we test them. So I think overall, we as an industry have an opportunity to go back to the basics of formulation and help educate consumers about different ingredients and their impact in formulations; and not just add ingredients because they are popular or trending. We know that ingredients may work differently in different base formulations—in a water gel versus let’s say an emulsion. Understanding the impact of different formulation parameters on ingredient efficacy (both bioactivity and permeation/absorption) is critical to formulating products with minimal ingredients that add value to the end benefit. This is how it used to be done. So I think it’s time to go back to the basics of formulation. Prithwiraj Maitra, Ph.D. (PM), executive director of global skin care R&D for formulation, tech transfer, external innovation and skin biology at AbbVie, explained in a recent interview.

🤔 kenne nur gefüllte Quarktasche 🤭😂

Was ist eine gefühlte Tatsache? 🤔

"Immer wenn der Kurs so niedrig ist kommt urplötzlich ein Firmen update?" Das ist wohl eher eine gefühlte Tatsache, als tatsächliche Realität.

„Der Weg ist das Ziel.“

denn…

„Es spielt keine Rolle, wie langsam Sie gehen, solange Sie nicht aufhören.“

Also ich bin zu 100% überzeugt, dass das Zeug funktioniert oder eben nicht

Es funktioniert ja, das wissen wir doch schon 😏

Naja, entweder das funktioniert alles, was da so erzählt wird, dann stehen wir in ein paar Jahren wo ganz anders, oder eben nicht, dann wird hier nicht so arg viel passieren 🥲😂

Ich auch Ned. Da Verkauf ich sofort bei 1,5 😁

Och…. Volatilität von 1,50 bis 0,0875 mach ich jetzt gerne einmal mit. Ich schwöre! Ich heule nicht

Und wenn dann insti‘s bei SBM mitspielen heulen alle rum wegen der hohen Volatilität.. hat alles vor- und Nachteile, institutionelle Investoren sind sicher auch nicht der heilige Gral für pennystocks, nur meine Meinung..